ab246832 Search Results


picrosirius red solution  (Danaher Inc)
99
Danaher Inc picrosirius red solution
Apabetalone blocks TGF-β1-induced HRMC activation. ( A ): HRMCs were treated with TGF-β1 ± BETi or TGFBRi for 24 h followed by gene expression analysis by real-time PCR ( n = 5). ( B ): Representative images of HRMCs treated with TGF-β1 ± apabetalone for 48 h, followed by immunofluorescence microscopy for α-SMA (green); nuclei were stained with DAPI (blue); apa = apabetalone. ( C ): Fluorescence intensity of α-SMA was quantified as percent of the image area. ( D ): Collagen gel contraction was evaluated after 4 days of treatment ( n = 6). ( E ) Collagen deposition was evaluated by <t>picrosirius</t> red staining after 5 days of treatment ( n = 4). Data in bar graphs are the mean ± SD. Statistical analysis by one-way ANOVA followed by Dunnett’s Multiple Comparison Test. *** p < 0.001, ** p < 0.01, NS not significant. ACTA2: α-SMA gene. α-SMA: alpha smooth muscle actin. TGF-β1: Transforming growth factor β1. Apabetalone: BD2-selective BET inhibitor. JQ1: pan-BET inhibitor. MZ1: PROTAC that directs BET proteins for degradation. TGFBRi: small molecule inhibitor of the TGF-β receptor.
Picrosirius Red Solution, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ab246832/pmc10295623-93-4-7?v=Danaher+Inc
Average 99 stars, based on 1 article reviews
picrosirius red solution - by Bioz Stars, 2026-08
99/100 stars
  Buy from Supplier
picro-sirius red solution  (Advisains)
99
Advisains picro-sirius red solution
Apabetalone blocks TGF-β1-induced HRMC activation. ( A ): HRMCs were treated with TGF-β1 ± BETi or TGFBRi for 24 h followed by gene expression analysis by real-time PCR ( n = 5). ( B ): Representative images of HRMCs treated with TGF-β1 ± apabetalone for 48 h, followed by immunofluorescence microscopy for α-SMA (green); nuclei were stained with DAPI (blue); apa = apabetalone. ( C ): Fluorescence intensity of α-SMA was quantified as percent of the image area. ( D ): Collagen gel contraction was evaluated after 4 days of treatment ( n = 6). ( E ) Collagen deposition was evaluated by <t>picrosirius</t> red staining after 5 days of treatment ( n = 4). Data in bar graphs are the mean ± SD. Statistical analysis by one-way ANOVA followed by Dunnett’s Multiple Comparison Test. *** p < 0.001, ** p < 0.01, NS not significant. ACTA2: α-SMA gene. α-SMA: alpha smooth muscle actin. TGF-β1: Transforming growth factor β1. Apabetalone: BD2-selective BET inhibitor. JQ1: pan-BET inhibitor. MZ1: PROTAC that directs BET proteins for degradation. TGFBRi: small molecule inhibitor of the TGF-β receptor.
Picro Sirius Red Solution, supplied by Advisains, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ab246832/custom%40ab246832%4041630990?v=Advisains
Average 99 stars, based on 1 article reviews
picro-sirius red solution - by Bioz Stars, 2026-08
99/100 stars
  Buy from Supplier

Image Search Results


Apabetalone blocks TGF-β1-induced HRMC activation. ( A ): HRMCs were treated with TGF-β1 ± BETi or TGFBRi for 24 h followed by gene expression analysis by real-time PCR ( n = 5). ( B ): Representative images of HRMCs treated with TGF-β1 ± apabetalone for 48 h, followed by immunofluorescence microscopy for α-SMA (green); nuclei were stained with DAPI (blue); apa = apabetalone. ( C ): Fluorescence intensity of α-SMA was quantified as percent of the image area. ( D ): Collagen gel contraction was evaluated after 4 days of treatment ( n = 6). ( E ) Collagen deposition was evaluated by picrosirius red staining after 5 days of treatment ( n = 4). Data in bar graphs are the mean ± SD. Statistical analysis by one-way ANOVA followed by Dunnett’s Multiple Comparison Test. *** p < 0.001, ** p < 0.01, NS not significant. ACTA2: α-SMA gene. α-SMA: alpha smooth muscle actin. TGF-β1: Transforming growth factor β1. Apabetalone: BD2-selective BET inhibitor. JQ1: pan-BET inhibitor. MZ1: PROTAC that directs BET proteins for degradation. TGFBRi: small molecule inhibitor of the TGF-β receptor.

Journal: Biomedicines

Article Title: Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal Impairment

doi: 10.3390/biomedicines11061663

Figure Lengend Snippet: Apabetalone blocks TGF-β1-induced HRMC activation. ( A ): HRMCs were treated with TGF-β1 ± BETi or TGFBRi for 24 h followed by gene expression analysis by real-time PCR ( n = 5). ( B ): Representative images of HRMCs treated with TGF-β1 ± apabetalone for 48 h, followed by immunofluorescence microscopy for α-SMA (green); nuclei were stained with DAPI (blue); apa = apabetalone. ( C ): Fluorescence intensity of α-SMA was quantified as percent of the image area. ( D ): Collagen gel contraction was evaluated after 4 days of treatment ( n = 6). ( E ) Collagen deposition was evaluated by picrosirius red staining after 5 days of treatment ( n = 4). Data in bar graphs are the mean ± SD. Statistical analysis by one-way ANOVA followed by Dunnett’s Multiple Comparison Test. *** p < 0.001, ** p < 0.01, NS not significant. ACTA2: α-SMA gene. α-SMA: alpha smooth muscle actin. TGF-β1: Transforming growth factor β1. Apabetalone: BD2-selective BET inhibitor. JQ1: pan-BET inhibitor. MZ1: PROTAC that directs BET proteins for degradation. TGFBRi: small molecule inhibitor of the TGF-β receptor.

Article Snippet: Collagen was stained with picrosirius red solution (Abcam # ab246832) for 60 min, followed by destaining with 0.1 N HCl.

Techniques: Activation Assay, Gene Expression, Real-time Polymerase Chain Reaction, Immunofluorescence, Microscopy, Staining, Fluorescence, Comparison